Opportunities for the discovery of novel therapies for fibrotic diseases.
Franklin
T J
TJ
Cancer Research Department, Zeneca Pharmaceuticals, Macclesfield, Ches., UK.
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000818:Animals; D003094:Collagen / Q000378:metabolism; D016232:Endothelins / Q000037:antagonists & inhibitors; D005355:Fibrosis / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D011393:Procollagen-Proline Dioxygenase / Q000037:antagonists & inhibitors; D008249:Protein-Lysine 6-Oxidase / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors
D016232:Endothelins; D016212:Transforming Growth Factor beta; D000804:Angiotensin II; D003094:Collagen; D011393:Procollagen-Proline Dioxygenase; D008249:Protein-Lysine 6-Oxidase; D020794:Receptor Protein-Tyrosine Kinases